Search research articles
Contact Us
Filters
Showing results (101-110 of 167) with videos related to
Page
of 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Journal for Immunotherapy of Cancer
|
October 19, 2021
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
Joël Guigay, Keun-Wook Lee, Manish R Patel, et al.
Breast Cancer Research and Treatment
|
August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Vandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2018
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Maura N Dickler, Cristina Saura, Donald A Richards, et al.
Optics Express
|
December 25, 2015
Optical and radiometric models of the NOMAD instrument part I: the UVIS channel
Ann C Vandaele, Yannick Willame, Cédric Depiesse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2020
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
Ben Sidders, Pei Zhang, Kelly Goodwin, et al.
Journal for Immunotherapy of Cancer
|
October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Andrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
JAMA Oncology
|
January 25, 2019
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
Mary L Disis, Matthew H Taylor, Karen Kelly, et al.
JAMA Oncology
|
January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial
Raffit Hassan, Anish Thomas, John J Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2017
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S Miller, Chihiro Morishima, Douglas G McNeel, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 167) with videos related to
Sort By:
Page
of 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 5, 2017
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B Apolo, Jeffrey R Infante, Ani Balmanoukian, et al.
Journal for Immunotherapy of Cancer
|
October 19, 2021
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
Joël Guigay, Keun-Wook Lee, Manish R Patel, et al.
Breast Cancer Research and Treatment
|
August 2, 2019
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer
Vandana G Abramson, Mafalda Oliveira, Andrés Cervantes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2018
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
Maura N Dickler, Cristina Saura, Donald A Richards, et al.
Optics Express
|
December 25, 2015
Optical and radiometric models of the NOMAD instrument part I: the UVIS channel
Ann C Vandaele, Yannick Willame, Cédric Depiesse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 19, 2020
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
Ben Sidders, Pei Zhang, Kelly Goodwin, et al.
Journal for Immunotherapy of Cancer
|
October 10, 2020
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Andrea B Apolo, John A Ellerton, Jeffrey R Infante, et al.
JAMA Oncology
|
January 25, 2019
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial
Mary L Disis, Matthew H Taylor, Karen Kelly, et al.
JAMA Oncology
|
January 4, 2019
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial
Raffit Hassan, Anish Thomas, John J Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2017
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S Miller, Chihiro Morishima, Douglas G McNeel, et al.
Page
of 17